Request a copy

Full Text

• R.Siegel, D.Naishadham, A.Jemal Cancer statistics, 2013. CA Cancer J Clin [Internet]. 2013;63(1):11–30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23335087
• Y.-J.Bang, E.Van Cutsem, A.Feyereislova, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet [Internet].2010;376(9742):687–697. Available from: http://linkinghub.elsevier.com/retrieve/pii/S014067361061121X•• The study showed an additional median survival benefit of over 2 months with trastuzumab combined with 5-FU and cisplatin compared with chemotherapy alone in a first-line patient setting whose tumor was characterized by HER2 overexpression.
• Y.Yamada, K.Higuchi, K.Nishikawa, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol [Internet].2015;26(1):141–148. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25316259• The study showed the non-inferiority of oxaliplatin/S-1 over cisplatin/S-1 in chemotherapy-naïve AGC patients.
• A.D.Wagner, W.Grothe, J.Haerting, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol [Internet]. 2006;24(18):2903–2909. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16782930
• M.Dank, J.Zaluski, C.Barone, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol [Internet].2008;19(8):1450–1457. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18558665• The study demonstrated the non-inferiority of irinotecan plus 5-FU over cisplatin/5-FU. So this doublet may be recommended as an alternative choice in front-line treatment of AGC when a platinum-free regimen is required.
• S.-E.Al-Batran, J.T.Hartmann, S.Probst, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. J Clin Oncol [Internet]. 2008;26(9):1435–1442. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18349393
• Y.-K.Kang, W.-K.Kang, D.-B.Shin, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20(4):666–673.
• J.A.Ajani, W.Rodriguez, G.Bodoky, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010;28(9):1547–1553.• The study showed that cisplatin/S-1 is non-inferior to cisplatin/infusional 5-FU, with a sefety toxicity profile in AGC patients.
• E.Van Cutsem, V.M.Moiseyenko, S.Tjulandin, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol [Internet]. 2006;24(31):4991–4997. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17075117
• D.Cunningham, N.Starling, S.Rao, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36–46.•• The study investigated the optimal structure of triplets and suggested EOX as the optimal first-line regimen for fit AGC patients.
• R.Guimbaud, C.Louvet, P.Ries, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup Fédération Francophone de Cancérologie Digestive, Féd. J Clin Oncol [Internet]. 2014;32(31):3520–3526. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25287828
• A.Ohtsu, M.A.Shah, E.Van Cutsem, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol [Internet]. 2011;29(30):3968–3976. Available from: http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2011.36.2236
• F.Lordick, Y.-K.Kang, H.-C.Chung, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol [Internet]. 2013;14(6):490–499. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1470204513701025
• T.Waddell, I.Chau, D.Cunningham, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol [Internet]. 2013;14(6):481–489. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1470204513700962
• J.R.Hecht, Y.-J.Bang, S.K.Qin, et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC- A randomized phase III trial. J Clin Oncol [Internet]. 2015;34(5):443–451. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26628478
• W.Koizumi, H.Narahara, T.Hara, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215–221.
• M.-H.Ryu, E.Baba, K.H.Lee, et al. Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS). Ann Oncol [Internet]. 2015;26(10):2097–2101. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26216386
• B.Chuah, B.-C.Goh, S.-C.Lee, et al. Comparison of the pharmacokinetics and pharmacodynamics of S-1 between caucasian and East Asian patients. Cancer Sci [Internet]. 2011;102(2):478–483. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21143703
• C.Tournigand, T.André, F.Bonnetain, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the multicenter international study of oxaliplatin, fluorouracil, and leucovorin in the adjuvant tre. J Clin Oncol [Internet]. 2012;30(27):3353–3360. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22915656
• Y.Mochizuki, N.Ohashi, H.Kojima, et al. CPT-11 as a second-line treatment for patients with advanced/metastatic gastric cancer who failed S-1 (CCOG0702). Cancer Chemother Pharmacol [Internet]. 2013;72(3):629–635. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23881212
• T.Hamaguchi, K.Shirao, A.Ohtsu, et al. A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the gastrointestinal oncology group of the Japan clinical oncology group (JCOG0109-DI trial). Gastric Cancer [Internet]. 2011;14(3):226–233. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21503598
• H.J.Chon, S.Y.Rha, H.S.Park, et al. Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer. Cancer Chemother Pharmacol [Internet]. 2011;68(4):991–999. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3180611&tool=pmcentrez&rendertype=abstract
• S.J.Sym, J.Hong, J.Park, et al. A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy. Cancer Chemother Pharmacol [Internet]. 2013;71(2):481–488. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23192279
• T.Ando, A.Hosokawa, S.Kajiura, et al. Efficacy of weekly paclitaxel in patients with advanced gastric cancer refractory to docetaxel-based chemotherapy. Gastric Cancer [Internet]. 2012;15(4):427–432. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22252156
• K.Shitara, S.Yuki, D.Tahahari, et al. Randomised phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer. Br J Cancer [Internet]. 2014;110(2):271–277. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3899763&tool=pmcentrez&rendertype=abstract
• Y.Sasaki, T.Nishina, H.Yasui, et al. Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer. Cancer Sci [Internet]. 2014;105(7):812–817. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24716542
• Y.Zheng, W.Fang, C.Mao, et al. Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a phase II study. Cancer Chemother Pharmacol [Internet]. 2014;74(3):503–509. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25038612
• X.-D.Zhang, Y.-Q.Shu, J.Liang, et al. Combination chemotherapy with paclitaxel, cisplatin and fluorouracil for patients with advanced and metastatic gastric or esophagogastric junction adenocarcinoma: a multicenter prospective study. Chin J Cancer Res. [Internet]. 2012;24(4):291–298. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3551331&tool=pmcentrez&rendertype=abstract
• R.Lin, N.Fan, G.Wu, et al. A phase 2 study of fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin as a salvage treatment in patients with refractory or relapsed advanced gastric cancer. J Chemother [Internet]. 2015;27(1):52–56. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24964957
• S.J.Sym, H.M.Chang, H.J.Kang, et al. A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer. Cancer Chemother. Pharmacol. [Internet]. 2008;63(1):1–8. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-39149107799&partnerID=40&md5=3ac4b19629b2116fd538fd6c6c11106a
• F.Lv, X.Liu, B.Wang, et al. S-1 monotherapy as second line chemotherapy in advanced gastric cancer patients previously treated with cisplatin/infusional fluorouracil. Int J Clin Exp Pathol [Internet]. 2014;7(7):4274–4279. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4129044&tool=pmcentrez&rendertype=abstract
• M.B.Miranda, J.T.Hartmann, S.E.Al-Batran, et al. Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study. J Cancer Res Clin Oncol [Internet]. 2014;140(5):829–837. Available from: //wos
• D.S.Zhang, Y.Jin, H.Y.Luo, et al. Pemetrexed for previously treated patients with metastatic gastric cancer: a prospective phase II study. Br J Cancer [Internet]. 2015;112(2):266–270. Available from: http://www.nature.com/doifinder/10.1038/bjc.2014.607
• J.Jeong, H.-C.Jeung, S.Y.Rha, et al. Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer. Ann Oncol [Internet]. 2008;19(6):1135–1140. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18272910
• P.C.Thuss-Patience, A.Kretzschmar, D.Bichev, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer–a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer [Internet].2011;47(15):2306–2314. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21742485• The first study that compared chemotherapy to BSC in recurrent disease, demonstrating 2-month survival gain with active treatment.
• J.H.Kang, L.S.Il, D.H.Lim, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol [Internet]. 2012;30(13):1513–1518. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22412140
• H.E.R.Ford, A.Marshall, J.A.Bridgewater, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol [Internet]. 2014;15(1):78–86. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24332238
• S.Hironaka, S.Ueda, H.Yasui, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 tria. J Clin Oncol [Internet]. 2013;31(35):4438–4444. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24190112
• K.Higuchi, S.Tanabe, K.Shimada, et al. Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801/BIRIP trial). Eur J Cancer [Internet]. 2014;50(8):1437–1445. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24560487
• K.Nishikawa, K.Fujitani, H.Inagaki, et al. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial. Eur J Cancer [Internet]. 2015;51(7):808–816. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25797356
• K.Tanabe, M.Fujii, K.Nishikawa, et al. Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05). Ann Oncol [Internet]. 2015;26(9):1916–1922. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26109630
• C.S.Fuchs, J.Tomasek, C.J.Yong, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet (London, England) [Internet].2014;383(9911):31–39. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24094768•• The study showed the benefit of the anti-VEGF-s ramucirumab, that is actually regarded as the only one alternative to chemotherapy in AGC patients after first-line progression.
• H.Wilke, K.Muro, E.Van Cutsem, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol [Internet].2014;15(11):1224–1235. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25240821•• The study recognized ramucirumab and paclitaxel combination as new standard second-line treatment for AGC patients.
• T.Satoh, R.-H.Xu, H.C.Chung, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN–a randomized, phase III study. J Clin Oncol [Internet].2014;32(19):2039–2049. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24868024• The study showed benefit in the addition of lapatinib to paclitaxel, but only in patients with intense HER2 immunoistochemical staining (3+).
• A.Ohtsu, J.A.Ajani, Y.-X.Bai, et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol [Internet]. 2013;31(31):3935–3943. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24043745
• W.Koizumi, M.Kurihara, A.Satoh, et al. Phase 1/11 study of bi-weekly irinotecan plus cisplatin in the treatment of advanced gastric cancer. Anticancer Res [Internet]. 25(2B):1257–1262. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15865075
• W.Koizumi, S.Morita, Y.Sakata. A randomized phase III trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE Trial). Jpn J Clin Oncol [Internet]. 2015;45(3):303–306. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4340275&tool=pmcentrez&rendertype=abstract
• T.Browder, C.E.Butterfield, B.M.Kräling, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res [Internet]. 2000;60(7):1878–1886. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10766175
• G.Klement, S.Baruchel, J.Rak, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest [Internet]. 2000;105(8):R15–24. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=517491&tool=pmcentrez&rendertype=abstract
• A.Romiti, M.C.Cox, I.Sarcina, et al. Metronomic chemotherapy for cancer treatment: a decade of clinical studies. Cancer Chemother Pharmacol [Internet]. 2013;72(1):13–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23475105
• S.He, J.Shen, L.Hong, et al. Capecitabine “metronomic” chemotherapy for palliative treatment of elderly patients with advanced gastric cancer after fluoropyrimidine-based chemotherapy. Med Oncol [Internet]. 2012;29(1):100–106. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21264547
• A.Romiti, C.E.Onesti, M.Roberto, et al. Continuous, low-dose capecitabine for patients with recurrent colorectal cancer. Med Oncol [Internet]. 2015;32(3):54. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25638466
• J.Miger, A.Holmqvist, S.X-FS, et al. Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer. Med Oncol [Internet]. 2014;31(3):870. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3933740&tool=pmcentrez&rendertype=abstract
• M.Roberto, A.Romiti, C.E.Onesti, et al. A metronomic schedule as salvage chemotherapy for upper gastrointestinal tract cancer. Anticancer Drugs [Internet]. 2015. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26473528
• A.J.Bass, V.Thorsson, I.Shmulevich, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature [Internet]. 2014;513(7517):202–209. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4170219&tool=pmcentrez&rendertype=abstract
• M.-H.Ryu, C.Yoo, J.G.Kim, et al. Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. Eur J Cancer [Internet]. 2015;51(4):482–488. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25661103
• Y.-K.Kang, S.Y.Rha, P.Tassone, et al. A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. Br J Cancer [Internet]. 2014;111(4):660–666. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4134501&tool=pmcentrez&rendertype=abstract
• Y.-C.Shen, C.-P.Li, C.-J.Yen, et al. Phase II multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer. Oncology [Internet]. 2014;87(2):104–113. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25011938
• T.Iveson, R.C.Donehower, I.Davidenko, et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Lancet Oncol [Internet]. 2014;15(9):1007–1018. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24965569
• F.-H.Han, H.-M.Li, D.-H.Zheng, et al. The effect of the expression of vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 on the clinical outcome in patients with gastric carcinoma. Eur J Surg Oncol [Internet]. 2010;36(12):1172–1179. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20888167
• E.Van Cutsem, S.De Haas, Y.-K.Kang, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol [Internet]. 2012;30(17):2119–2127. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22565005
• M.Martin-Richard, R.Gallego, C.Pericay, et al. Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study. Invest New Drugs [Internet]. 2013;31(6):1573–1579. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24077981
• M.Moehler, A.Mueller, J.T.Hartmann, et al. An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Eur J Cancer [Internet]. 2011;47(10):1511–1520. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21561763
• Y.-J.Bang, Y.-K.Kang, W.K.Kang, et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs [Internet]. 2011;29(6):1449–1458. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3171673&tool=pmcentrez&rendertype=abstract
• J.H.Yi, J.Lee, S.H.Park, et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. Br J Cancer [Internet]. 2012;106(9):1469–1474. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3341944&tool=pmcentrez&rendertype=abstract
• T.Doi, K.Muro, N.Boku, et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol [Internet]. 2010;28(11):1904–1910. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20231677
• D.H.Yoon, M.-H.Ryu, Y.S.Park, et al. Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. Br J Cancer [Internet]. 2012;106(6):1039–1044. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3304416&tool=pmcentrez&rendertype=abstract
• S.J.Lee, J.Lee, J.Lee, et al. Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients. Invest New Drugs [Internet]. 2013;31(6):1580–1586. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24013904
• R.K.Ramanathan, S.L.McDonough, H.F.Kennecke, et al. Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: a SWOG cooperative group trial (S1005). Cancer [Internet]. 2015. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25827820
• J.A.Chan, L.S.Blaszkowsky, P.C.Enzinger, et al. A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol [Internet]. 2011;22(6):1367–1373. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3493129&tool=pmcentrez&rendertype=abstract
• K.R.Schoennemann, J.K.Bjerregaard, T.P.Hansen, et al. Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum. Gastric Cancer [Internet]. 2011;14(3):219–225. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21409520
• N.C.Tebbutt, M.M.Parry, D.Zannino, et al. Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial. Br J Cancer [Internet]. 2013;108(4):771–774. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3590676&tool=pmcentrez&rendertype=abstract
• T.Satoh, K.H.Lee, S.Y.Rha, et al. Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer. Gastric Cancer [Internet]. 2015;18(4):824–832. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4572054&tool=pmcentrez&rendertype=abstract
• Y.-K.Kang, K.Muro, M.-H.Ryu, et al. A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer. Invest New Drugs [Internet]. 2014;32(2):355–361. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24337769
• M.A.Shah, Z.A.Wainberg, D.V.T.Catenacci, et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. Plos One [Internet]. 2013;8(3):e54014. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3597709&tool=pmcentrez&rendertype=abstract
• J.Li, S.Qin, J.Xu, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol [Internet]. 2013;31(26):3219–3225. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23918952
• S.Qin. Phase III study of apatinib in advanced gastric cancer: a randomized, double-blind, placebo-controlled trial. ASCO Annu Meet Proc [Internet]. 2014. Available from: http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/4003• The study on abstract discussed the effect of a new VEGFR-2 tyrosine kinase inhibitor, which prompted a statistically significant OS advantage in heavily pretreated patients.
• M.Tatematsu, T.Tsukamoto, T.Mizoshita. Role of Helicobacter pylori in gastric carcinogenesis: the origin of gastric cancers and heterotopic proliferative glands in Mongolian gerbils. Helicobacter [Internet]. 2005;10(2):97–106. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15810939
• A.Murphy, R.J.Kelly. Immunotherapy in upper GI malignancies. Curr Treat Options Oncol [Internet]. 2015;16(5):20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25859830
• Y.Sato, M.Kondo, S.Kohashi, et al. A randomized controlled study of immunochemotherapy with OK-432 after curative surgery for gastric cancer. J Immunother [Internet]. 27(5):394–397. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15314548
• H.Nakazato, A.Koike, S.Saji, et al. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet (London, England) [Internet]. 1994;343(8906):1122–1126. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7910230
• L.Shi, Q.Zhou, J.Wu, et al. Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol Immunother [Internet]. 2012;61(12):2251–2259. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3506195&tool=pmcentrez&rendertype=abstract
• H.-C.Jeung, Y.W.Moon, S.Y.Rha, et al. Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up. Ann Oncol [Internet].2008;19(3):520–526. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18029971• The study is the first phase III trial that showed a survival advantage of immunotherapy combined with chemotherapy in gastric adenocarcinoma, but in the adjuvant setting.
• A.G.Raufi, S.J.Klempner. Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations. J Gastrointest Oncol [Internet]. 2015;6(5):561–569. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4570917&tool=pmcentrez&rendertype=abstract
• H.Saito, H.Kuroda, T.Matsunaga, et al. Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer. J Surg Oncol [Internet]. 2013;107(5):517–522. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23129549
• T.Tamura, M.Ohira, H.Tanaka, et al. Programmed DEATH-1 LIGand-1 (PDL1) expression is associated with the prognosis of patients with stage II/III gastric cancer. Anticancer Res [Internet]. 2015;35(10):5369–5376. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26408698
• A.M.Intlekofer, C.B.Thompson. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol [Internet]. 2013;94(1):25–39. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3685017&tool=pmcentrez&rendertype=abstract
• N.Segal, S.Antonia, J.Brahmer. Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. J Clin Oncol [Internet]. 2014. Available from: https://scholar.google.it/scholar?q=Preliminary+data+from+a+multi-arm+expansion+study++of+MEDI4736%2C+an+anti-PD-L1+antibody.&btnG=&hl=it≈sdt=0%2C5#0
• K.Muro, H.C.Chung, V.Shankaran, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016. May 3. pii: S1470-2045(16)00175-3. doi:10.1016/1470-2045(16)00175-3. [Epub ahead of print].• The KEYNOTE-012 trial tested the role of pembrolizumab in refractory PD-L1 positive gastric cancer, showing some good results. However, more study is needed to confirm these data.
• R.De Angelis, M.Sant, M.P.Coleman, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol [Internet]. 2013;2045(13):1–12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24314615
• X.Paoletti, K.Oba, Y.-J.Bang, et al. Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis. J Natl Cancer Inst [Internet]. 2013;105(21):1667–1670. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24108811
• N.André, M.Carré, E.Pasquier. Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol. 2014;11(7):413–431. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24913374